Profile data is unavailable for this security.
About the company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
- Revenue in USD (TTM)522.00k
- Net income in USD-10.79m
- Incorporated2004
- Employees7.00
- LocationLexaria Bioscience Corp100 - 740 MCCURDY ROADKELOWNA V1X 2P7CanadaCAN
- Phone+1 (250) 765-6424
- Fax+1 (604) 685-7602
- Websitehttps://www.lexariabioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gelteq Ltd | 117.10k | -4.70m | 8.51m | 7.00 | -- | 0.7618 | -- | 72.68 | -0.4977 | -0.4977 | 0.0124 | 1.04 | 0.0078 | -- | 0.5155 | 16,728.25 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Biofrontera Inc | 37.17m | -17.57m | 9.07m | 92.00 | -- | -- | -- | 0.2441 | -1.84 | -1.84 | 4.07 | -0.2216 | 2.19 | 2.44 | 9.45 | 403,967.40 | -103.57 | -48.03 | -339.69 | -77.55 | 64.41 | 48.93 | -47.28 | -60.99 | 0.8033 | -47.48 | 2.37 | -- | 9.54 | 7.35 | 11.78 | -- | -35.51 | -- |
| Cuprina Holdings (Cayman) Ltd | 24.03k | -2.24m | 9.22m | 14.00 | -- | 1.52 | -- | 383.54 | -0.1234 | -0.1234 | 0.0013 | 0.2835 | 0.0049 | 13.39 | 0.7976 | 1,716.66 | -44.56 | -- | -131.50 | -- | -69.27 | -- | -9,194.46 | -- | 3.58 | -306.25 | 0.0244 | -- | -52.05 | -- | -39.39 | -- | -- | -- |
| Integrated Biopharma Inc | 53.43m | 672.00k | 9.31m | 153.00 | 14.14 | 0.4543 | 9.40 | 0.1742 | 0.0212 | 0.0212 | 1.71 | 0.6597 | 2.07 | 4.45 | 12.77 | 349,183.00 | 2.60 | 9.98 | 3.28 | 13.68 | 9.75 | 10.74 | 1.26 | 4.58 | 1.92 | -- | 0.0072 | -- | 8.02 | 0.5933 | 482.30 | -30.67 | -0.8556 | -- |
| CV Sciences Inc | 14.37m | -1.48m | 9.37m | 47.00 | -- | 6.09 | -- | 0.6525 | -0.008 | -0.008 | 0.078 | 0.0084 | 1.87 | 1.67 | 34.74 | 305,659.60 | -19.21 | -44.92 | -66.32 | -105.32 | 47.04 | 42.89 | -10.29 | -49.08 | 0.2125 | -2.02 | 0.3829 | -- | -1.87 | -21.80 | -177.18 | -- | -56.43 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 9.52m | 233.00 | 0.0651 | 0.001 | 2.47 | 0.1345 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Bon Natural Life Ltd | 18.67m | -1.99m | 10.12m | 96.00 | 18.63 | 0.2316 | -- | 0.5418 | 0.088 | 0.088 | 6.74 | 7.08 | 0.2541 | 6.07 | 1.64 | 194,486.40 | -2.79 | 5.82 | -3.97 | 7.86 | 20.77 | 28.53 | -10.98 | 10.83 | 1.61 | -4.44 | 0.1735 | 0.00 | -21.70 | 0.4899 | -577.58 | -- | 18.20 | -- |
| Nexgel Inc | 11.67m | -2.88m | 10.59m | 19.00 | -- | 2.04 | -- | 0.9075 | -0.3796 | -0.3796 | 1.53 | 0.6369 | 1.05 | 3.79 | 13.46 | 613,947.40 | -25.14 | -39.08 | -36.83 | -49.79 | 38.30 | 19.60 | -23.91 | -105.40 | 1.08 | -51.36 | 0.1439 | -- | 112.47 | 64.69 | -3.93 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -15.77m | 10.67m | 8.00 | -- | -- | -- | -- | -0.600 | -0.600 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -65.57 | -112.46 | -136.47 | -257.78 | -- | -- | -- | -- | -- | -27.77 | 0.0854 | -- | -- | -- | -97.75 | -- | -- | -- |
| Cellectar Biosciences Inc | 0.00 | -18.85m | 13.95m | 11.00 | -- | 1.40 | -- | -- | -10.78 | -10.78 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -72.62 | -104.57 | -141.24 | -133.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.23 | -- | 33.54 | -- |
| Lexaria Bioscience Corp | 522.00k | -10.79m | 15.49m | 7.00 | -- | 2.82 | -- | 29.68 | -0.5743 | -0.5743 | 0.0272 | 0.221 | 0.0659 | -- | 2.97 | 74,571.43 | -136.35 | -102.60 | -145.39 | -105.78 | 100.00 | 87.95 | -2,069.41 | -1,579.38 | -- | -285.30 | 0.00 | -- | 52.05 | 17.53 | -105.37 | -- | 48.50 | -- |
| Hoth Therapeutics Inc | 0.00 | -12.16m | 15.82m | 2.00 | -- | 1.87 | -- | -- | -1.06 | -1.06 | 0.00 | 0.5442 | 0.00 | -- | -- | 0.00 | -138.61 | -129.47 | -154.67 | -144.30 | -- | -- | -- | -- | -- | -493.48 | 0.00 | -- | -- | -- | -4.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 26.85m | -49.38m | 17.47m | 233.00 | -- | -- | -- | 0.6506 | -2.98 | -2.98 | 1.62 | -1.85 | 0.6096 | 1.60 | 4.22 | 115,218.90 | -107.02 | -36.27 | -277.91 | -51.90 | 53.68 | 57.36 | -175.56 | -124.01 | 0.236 | -13.27 | -- | -- | -15.77 | 47.19 | -45.62 | -- | -55.67 | -- |
| Nutraproducts Inc | 0.00 | -821.94k | 20.12m | 0.00 | -- | 3.36 | -- | -- | -1.31 | -1.31 | 0.00 | 0.2973 | 0.00 | -- | -- | -- | -513.70 | -1,177.23 | -740.45 | -- | -- | -- | -- | -- | -- | -385.17 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 20.76m | 217.00 | -- | 0.1459 | -- | 6.53 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Natural Alternatives International Inc | 134.44m | -11.88m | 21.56m | 293.00 | -- | 0.3123 | -- | 0.1604 | -1.99 | -1.99 | 22.52 | 11.17 | 0.845 | 4.35 | 7.36 | 458,839.60 | -7.47 | 0.4593 | -9.15 | 0.5479 | 8.50 | 12.75 | -8.84 | 0.4296 | 1.01 | -2.56 | 0.1408 | 0.00 | 14.12 | 1.78 | -88.10 | -- | -4.46 | -- |
Data as of Feb 17 2026. Currency figures normalised to Lexaria Bioscience Corp's reporting currency: US Dollar USD
8.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invenomic Capital Management LPas of 30 Sep 2025 | 477.20k | 1.92% |
| Murchinson Ltd.as of 30 Sep 2025 | 419.59k | 1.69% |
| UBS Securities LLCas of 31 Dec 2025 | 361.30k | 1.45% |
| Geode Capital Management LLCas of 31 Dec 2025 | 219.72k | 0.88% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 154.45k | 0.62% |
| TD Securities (USA) LLCas of 30 Sep 2025 | 140.00k | 0.56% |
| Byrne Asset Management LLCas of 31 Dec 2025 | 105.50k | 0.42% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 94.17k | 0.38% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 39.30k | 0.16% |
| Virtu Americas LLCas of 30 Sep 2025 | 29.36k | 0.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
